Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer

  • 14 Accesses

Summary

Twenty-two orchiectomized men with progressive stage D2 prostate cancer were treated with a 3-week cycle of estramustine phosphate (EMP: from day 3 to day 21) and androgen priming (from day 1 to day 4). A partial response according to the NPCP-USA criteria was shown in 4 of 20 evaluable patients. Median progression-free survival of all patients was 24 weeks (range, 4–48) and median survival, 42 weeks (range, 4–112). Although in two cases treatment had to be stopped due to a marked increase in bone pain, no life-threatening side effects were observed. The androgen sensitivity of tumors was supported by the occurrence of increase in prostatic phosphatase and in bone pain in most patients. In this group of patients, androgen priming did not seem to potentiate the effectiveness of EMP, our results being comparable to those previously reported using EMP alone.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alison MR, Wright NA (1981) Growth kinetics. In: Duncan W (ed) Recent results in cancer research. Prostate cancer. Springer Verlag, Berlin Heidelberg New York, p 29

  2. 2.

    Andersson L, Berlin T, Boman J, Collste L, Edsmyr F, Esposti PL, Gustafsson H, Hedlund PO, Hultgren L, Leander G, Nordle O, Norlen H, Tillgard P (1980) Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol (Suppl) 55: 143

  3. 3.

    Benson RC Jr, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9(4): 341

  4. 4.

    Benson RC, Wear JB, Gill GM (1979) Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol 121: 452

  5. 5.

    Bjork P, Forsgren B, Gustafsson JA, Hogborg B (1982) Partial characterization and “quantitation” of a human prostatic estramustine-binding protein. Cancer Res 42: 1935

  6. 6.

    Coffey DS, Shimazaki J, Williams-Ashman HG (1968) Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 124: 184

  7. 7.

    Edsmyr F, Andersson L, Könyves I (1982) Estramustine phosphate (estracyt): Experimental studies and clinical experience. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams and Wilkins, Baltimore, London, p 253

  8. 8.

    English HF, Drago JR, Santen RJ (1985) Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate 7: 41

  9. 9.

    Forsgren B, Bjork P (1984) Specific binding of estramustine to prostatic proteins. Urology (Suppl) 23 (6): 34

  10. 10.

    Forgren B, Gustafsson JA, Pousette A, Hogberg B (1979) Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 β-estradiol. Cancer Res 39: 5155

  11. 11.

    Grossman HB, Kleinert EL, Lesser ML, Herr HW, Whitmore WF Jr (1981) Androgen stimulated chemotherapy in the Dunning R-3327 prostatic adenocarcinoma. Urol Res 9: 237

  12. 12.

    Lesser B, Bruchovsky N (1973) The effect of testosterone and 5 alfa-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochem Biophys Acta 308: 426

  13. 13.

    Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glode LM (1986) Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol 136: 1242

  14. 14.

    Pousette A, Bjork P, Carlstrom K, Forsgren B, Hogberg B, Gustafsson JA (1981) Influence of sex hormones on prostatic secretion protein, a major protein in rat prostate. Cancer Res 41: 688

  15. 15.

    Slack NH, Brady MF, Murphy GP and Investigatiors in National Prostatic Cancer Project (1984) A reexamination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 54: 564

  16. 16.

    Suarez AJ, Lamm DL, Radwin HM, Sarosdy M, Clark G, Osborne CK (1982) Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol 8: 261

  17. 17.

    Tew KD, Hartley B (1984) Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology (Suppl) 23 (6): 28

Download references

Author information

Correspondence to Francesco Boccardo.

Additional information

This study was partially supported by a grant of the Italian National Research Council, Special Project “Oncologia”, contract number 85.02188.44

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Boccardo, F., Decensi, A., Guarneri, D. et al. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. Cancer Chemother. Pharmacol. 22, 172–174 (1988). https://doi.org/10.1007/BF00257317

Download citation

Keywords

  • Prostate Cancer
  • Cancer Research
  • Androgen
  • Median Survival
  • Partial Response